Related Experiment Video
Updated: Jul 6, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10.7K
Multiple sclerosis and COVID-19: a bidirectional Mendelian randomization study.
Shitong Liu1, Yixin Liang2, Binbin Sheng1,3
1School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, China.
Frontiers in Immunology
|November 4, 2024
Summary
Genetic factors influence COVID-19 outcomes in multiple sclerosis (MS) patients. The SNP rs10191329 may reduce severe COVID-19 risk, while interferon beta treatment might offer protection.
Area of Science:
- Immunogenetics
- Neurology
- Infectious Diseases
Background:
- Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system.
- The impact of MS on COVID-19 outcomes and the role of genetic factors require further investigation.
- Interferon beta (IFNβ) is a common treatment for MS.
Purpose of the Study:
- To investigate the relationship between MS and COVID-19 outcomes using Mendelian randomization.
- To evaluate the influence of genetic factors, specifically SNP rs10191329, on COVID-19 susceptibility and severity in MS patients.
- To assess the effect of IFNβ treatment on COVID-19 outcomes in MS patients.
Main Methods:
- Mendelian randomization analysis utilizing genome-wide association study summary statistics.
- Selection of single-nucleotide polymorphisms (SNPs) strongly associated with MS.
- Examination of the impact of selected SNPs and IFNβ treatment on three COVID-19 outcomes: SARS-CoV-2 infection, hospitalized COVID-19, and severe COVID-19.
Main Results:
- A potential association between MS and increased COVID-19 risk was observed.
- Individuals with the rs10191329 SNP showed a reduced likelihood of developing severe COVID-19.
- No significant causal relationship was found between IFNβ treatment and COVID-19 outcomes in treated versus untreated MS patients, suggesting a potential protective effect of IFNβ.
Conclusions:
- Genetic factors, such as rs10191329, play a role in modulating COVID-19 outcomes in MS patients.
- IFNβ treatment may confer protective effects against SARS-CoV-2 infection in individuals with MS.
- Personalized treatment strategies considering genetic predispositions are crucial for managing MS patients during the COVID-19 pandemic.
Keywords:
COVID-19Mendelian randomizationinterferon betamultiple sclerosissingle nucleotide polymorphismMore Related Videos
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...